Stratec Se

Stratec Se Equity

The The Equity of Stratec Se (SBS.DE) as of Oct 14, 2026 is 237.32 M EUR. In the previous year, The Equity was 242.53 M EUR — a change of -2.15% (lower).

Equity

237.32 MEUR

YoY

-2.15%

Last updated:

In 2025, Stratec Se's equity was 237.32 M EUR, a -2.15% increase from the 242.53 M EUR equity in the previous year.

The Stratec Se Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
152.20 M EUR
Jan 1, 2019
159.01 M EUR
Jan 1, 2020
172.55 M EUR
Jan 1, 2021
205.76 M EUR
Jan 1, 2022
225.18 M EUR
Jan 1, 2023
233.33 M EUR
Jan 1, 2024
242.53 M EUR
Jan 1, 2025
237.32 M EUR
The Stratec Se Equity history
YEAREquityYoY
237.32 MEUR-2.15%
242.53 MEUR+3.95%
233.33 MEUR+3.62%
225.18 MEUR+9.44%
205.76 MEUR+19.25%
172.55 MEUR+8.51%
159.01 MEUR+4.47%
152.20 MEUR-3.57%
157.84 MEUR+9.82%
143.72 MEUR+10.32%
130.28 MEUR+16.27%
112.05 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Stratec Se's Equity

Stratec Se's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Stratec Se's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Stratec Se's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Stratec Se's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Stratec Se’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Stratec Se stock

The Equity of Stratec Se is 237.32 M EUR in 2025.

The Equity of Stratec Se changed from 242.53 M EUR to 237.32 M EUR, representing a -2.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Stratec Se since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Stratec Se historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Stratec Se

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Stratec Se